Proteomics: An overview

Inflammatory Bowel Diseases

Volumn 11, Issue 10, 2005, Pages 927-936

  Lawrance, Ian Craig ^a,b   Klopcic, Borut ^a   Wasinger, Valerie C ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AUTOANTIBODY;

DNA FINGERPRINTING; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; TISSUE MICROARRAY;

ANTIGEN-ANTIBODY REACTIONS; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MASS SPECTROMETRY; PROTEIN ARRAY ANALYSIS; PROTEIN INTERACTION MAPPING; PROTEOMICS;

EID: 26444479445     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000178264.41722.0f     Document Type: Review

References (72)

1. Anderson NG, Anderson NL, Human Proteins Index Project. Behring Inst. Mitt. 1979;63:169-210.
2. Kenyon G, et al. Defining the mandate of proteomics in the post-genomics era: workshop report. Mol Cell Proteomics. 2002;1:765-780.
3. Fakhrai-Rad H, et al. SNP discovery in pooled samples with mismatch repair detection. Genome Res. 2004;14:1404-1412.
4. Garcia-Blanco M, Baraniak A, Lasda E. Alternate splicing in disease and therapy. Nat Biotechnol. 2004;22:535-546.
5. Tyers M, Mann M. From genomics to proteomics. Nature. 2003;422:193-197.
6. Phizicky E, et al. Protein analysis on a proteomic scale. Nature. 2003; 422:208-215.
7. Ghaemmaghami S, et al. Global analysis of protein expression in yeast. Nat Biotechnol. 2003;425:737-741.
8. Wasinger VC, et al. Progress with gene-product mapping of the Mollicutes: mycoplasma genitalium. Electrophoresis. 1995;16:1090-1094.
9. Wasinger VC, Pollack JD, Humphery-Smith I. The proteome of Mycoplasma genitalium. Chaps-soluble component. Eur J Biochem. 2000; 267:1571-1582.
10. Lipton MS, et al. Global analysis of the Deinococcus radiodurans proteome by using accurate mass tags. Proc Natl Acad Sci USA. 2002; 99:11049-11054.
11. Margolis J, Kenrick KG. 2-dimensional resolution of plasma proteins by combination of polyacrylamide disc and gradient gel electrophoresis. Nature. 1969;221:1056-1057.
12. Robinson W, Steinman L, Utz P. Proteomics technologies for the study of autoimmune disease. Arthritis Rheum. 2002;46:885-893.
13. Quintana F, et al. Functional immunomics: microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes. Proc Natl Acad Sci USA. 2004;101(Suppl 2):14615-14621.
14. Lueking A, et al. Profiling of alopecia areata autoantigens based on protein microarray technology. Mol Cell Proteomics, 2005. MCP Papers. (in press).
15. Graham K, et al. High-throughput methods for measuring autoantibodies in systemic lupus erythematosus and autoimmune diseases. Autoimmunity. 2004;37:269-272.
16. van Niel G, et al. Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterology. 2001;121:337-349.
17. Thery C, et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol. 2001;166:7309-7318.
18. Volmer MW, et al. Tumor suppressor Smad4 mediates downregulation of the anti-adhesive invasion-promoting matricellular protein SPARC: Landscaping activity of Smad4 as revealed by a "secretome" analysis. Proteomics. 2004;4:1324-1334.
19. Volmer MW, et al. Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer. Proteomics. 2005.
20. Reed M, et al. TGF-beta 1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. J Cell Physiol. 1994;158:9-99.
21. Pavasant P. The synergistic effect of TGF-? and 1,25-dihydroxyvitamin D3 on SPARC synthesis and alkaline phosphatase activity in human pulp fibroblasts. Arch Oral Biol. 2003;48:717-722.
22. Shanker G, et al. Regulation of extracellular matrix proteins by transforming growth factor beta] in cultured pulmonary endothelial cells. Cell Biol Int. 1999;23:61-72.
23. Porter PL, et al. Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem. 1995;43:791-800.
24. Shankavaram UT, et al. Regulation of human monocyte matrix metalloproteinases by SPARC. J Cell Physiol. 1997;173:327-334.
25. Kader HA, et al. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol. 2005;100:414-423.
26. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet. 2001;10:445-456.
27. Lawrance IC, Lloyd F, Raye W. A role for SPARC in the extracellular matrix changes in IBD. Gastroenterology. 2004;126(Suppl 2):68-568.
28. Savani RC, et al. Bleomycin-induced pulmonary injury in mice deficient in SPARC. Am J Physiol Lung Cell Mol Physiol. 2000;279:L743-L750.
29. Lawrance I, et al. SPARC protects against chronic murine Inflammation-induced intestinal fibrosis. Gastroenterology. 2005;127(Suppl 2):9-99.
30. Gauthier DJ, et al. Utilization of a new biotinylation reagent in the development of a nondiscriminatory investigative approach for the study of cell surface proteins. Proteomics. 2004;4:3783-3790.
31. Jang JH, Hanash S. Profiling of the cell surface proteome. Proteomics. 2003;3:1947-1954.
32. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001; 411:355-365.
33. Lim YP, et al. Phosphoproteomic fingerprinting of epidermal growth factor signaling and anticancer drug action in human tumor cells. Mol Cancer Ther. 2003;2:1369-1377.
34. Kumagai S, et al. Platelet-derived growth factor and its receptors are expressed in areas of both active inflammation and active fibrosis in inflammatory bowel disease. Tohoku J Exp Med. 2001;195:21-33.
35. Fields S, Song O. A novel genetic system to detect protein-protein interactions. Nature. 1989;340:245-246.
36. Zhu H, et al. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature. 1999;400:687-693.
37. Ebisawa T, et al. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem. 2001;276:12477-12480.
38. Asano Y, et al. Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest. 2004;113: 253-264.
39. Li S, et al. A map of the interactome network of the metazoan C. elegans. Science. 2004;303:540-543.
40. Barrios-Rodiles M, et al. High-throughput mapping of a dynamic signaling network in mammalian cells. Science. 2005;307:1621-1625.
41. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 1975;250:4007-4021.
42. Klose J. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik. 1975;26:231-243.
43. Gygi SP, et al. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci USA. 2000;97:9390-9395.
44. Santoni V Molloy M, Rabilloud T. Membrane proteins and proteomics: un amour impossible? Electrophoresis. 2000;21:1054-1070.
45. Corthals GL, et al. The dynamic range of protein expression: a challenge for proteomic research. Electrophoresis. 2000;21:1104-1115.
46. Link AJ, et al. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol. 1999;17:676-682.
47. Washburn MP, Wolters D, Yates JR III. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol. 2001;19:242-247.
48. Fenn JB, et al. Electrospray ionization for large biomolecules. Science. 1989;246:64-71.
49. Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem. 1988;60:2299-2301.
50. Tanaka K, et al. Detection of high mass molecules by laser desorption time-of-flight mass spectrometry. Proceedings of the 2nd Japan-China Joint Symposium Mass Spectrometry. 1987, Osaka, Japan.
51. Shaw G. Rapid identification of proteins. Proc Natl Acad Sci USA. 1993;90:5138-5142.
52. Pappin DJ, Hojrup P, Bleasby AJ. Rapid identification of proteins by peptide-mass fingerprinting. Curr Biol. 1993;3:327-332.
53. Shen Y, et al. Nanoscale proteomics. Anal Bioanal Chem. 2004;378:1037-1045.
54. Omenn S, et al. A collaborative study of human serum and plasma proteins identified with 2 or more peptides matched by MS/MS analysis. Proteomics. 2005;6.
55. Gilbert S, Omenn DJS, Adamski M. Overview of the HUPO plasma protein Proteome project: results from the pilot phase with 35 collaboration laboratories and multiple analytical groups generating a core dataset of 3020 proteins and a publically-available database. Proteomics. 2005;6.
56. Sun W, et al. A systematical analysis of tryptic peptide identification with reverse phase liquid chromatography and electrospray ion trap mass spectrometry. Genomics Proteomics Bioinformatics. 2004;2:174-183.
57. Vitali B, et al. A proteomic view of Bifidobacterium infantis generated by multi-dimensional chromatography coupled with tandem mass spectrometry. Proteomics. 2004. (in press)
58. Templin M, et al. Protein microarrays: promising tools for proteomic research. Proteomics. 2003;3:2155-2166.
59. Templin M, et al. Protein microarray technology. Trends Biotechnol. 2002;20:160-166.
60. Schwenk J, et al. Cell microarrays: an emerging technology for the characterization of antibodies. Biotechniques. 2002;(Suppl):54-61.
61. Liotta L, et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell. 2003;3:317-325.
62. Usui-Aoki K, et al. A novel approach to protein expression profiling using antibody microarrays combined with surface plasmon resonance technology. Proteomics. 2005;5:2396-2401.
63. Espina V, et al. Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics. 2003;3:2091-2100.
64. Charboneau L, et al. Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic. 2002;1:305-315.
65. Nishizuka S, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci USA. 2003;100:14229-14234.
66. Beaven S, Abreu M. Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol. 2004;20:318-327.
67. Lueking A, Cahill D, Mullner S. Protein biochips: a new and versatile platform technology for molecular medicine. Drug Discov Today. 2005;10:789-794.
68. Lawrance IC, et al. A prospective comparative study of ASCA and ANCA in Chinese and Caucasian IBD patients. Am J Gastroenterol. 2004;99: 2186-2194.
69. Braunschweig T, Chung J, Hewitt S. Perspectives in tissue microarrays. Comb Chem High Throughput Screen. 2004;7:575-585.
70. Hewitt S. Design, construction, and use of tissue microarrays. Methods Mol Biol. 2004;264:61-72.
71. Rimm D, et al. Tissue microarray: a new technology for amplification of tissue resources. Cancer J. 2001;7:24-31.
72. Chung G, et al. Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis. Clin Cancer Res. 2001;7:4013-4020.